Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
NEW ORLEANS, Aug. 26, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 12, 2016 to file lead plaintiff applications in a securities class action lawsuit against Juno Therapeutics, Inc. (Nasdaq:JUNO), if they purchased the Company’s securities between June 4, 2016 and July 7, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Washington.
What You May Do
If you purchased shares of Juno and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by September 12, 2016.
About the Lawsuit
Juno and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
In May 2016, a patient in the Phase 2 trial of Juno’s lead product candidate died, after which Juno consulted with the FDA. In June, Juno issued a press release that touted “[l]ower side effects” and made partial, misleading disclosures—revealing that “Grade 3 or higher neurotoxicity was observed in 15/51 (29%) patients” in a Phase 1 trial, but did not disclose the patient death. Then, two other patients died in late June and early July, after which the FDA issued a clinical hold. On this news, the value of Juno’s stock plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
